Sunday, June 7, 2015

Body metrics

During my last visit to the IKN on 2/6/2015 my body metrics were as follows:

Weight  -  69 Kg
BMI       - 25.3
BP        - 122/69
Pulse    - 68 BPM
Oxygen level in body - 99%

I was given a clean bill. You may want to know my secret to good health? It is no secret actually. I t is all about exercising daily and eating well. The key to this is discipline and consistency.

For your information my body metrics hardly changed over the last two years. See table below:

Weight (Kg)
Body Fat
Actual age (1944)
Bio- age
Basal Metabolic Rate
Viseral fat
Trunk fat
Leg fat
Arm fat
Whole body fat
Trunk Muscle
Leg Muscle
Arm muscle
Whole body muscle

Keeping a record of your body metrics is a good way to maintain discipline and consistency.
As I grew older by 2 years, my bio-age remained the same. I had a slight improvement in my visceral and overall body fats. This is important to keep fats in the stomach and hormone levels stable. My body muscles were slightly up, but as expected building muscles gets more difficult with age.

I hope to maintain the same results come next year.

Take care 

Allen Lai

Serum PSA profile following Radiation Therapy for Prostrate Cancer: Implication for patterns of failure and definition of cure

Another Pub Med.Gov report in April 1998. Study still valid.



A reference range of prostate-specific antigen (PSA) values compatible with cure following radiotherapy (RT) for prostate cancer (PCa) has yet to be established. Various thresholds, as low as 0.5 ng/mL, have been used to define biochemical disease-free status. We report PSA profiles in 118 patients who were systematically biopsied following standard RT, with a minimum 4-year follow-up.


One hundred eighteen patients were treated with standard external beam RT from May 1987 to October 1991, and were followed prospectively with transrectal ultrasound (TRUS)-guided biopsies and measurement of serum PSA levels. Stage distribution was as follows: T1b: 25 patients, T2a: 27 patients, T2b/c: 42 patients, T3: 23 patients, T4: 1 patient. Median follow-up for patients without clinical failure is 68 months (range 48 to 108). Treatment failures were categorized as biochemical (biochemical failure [chemF]: PSA level of 2.0 ng/mL or more and greater than 1 ng/mL over nadir), local (local failure [LF]: positive biopsy and PSA level greater than 2.0), and distant failure (DF).


PCa recurred in 55% of patients: 38% LF (n = 45; 30 isolated and 15 with DF), 25% DF (n = 30; 15 isolated and 15 with LF), and 4% chemF (n = 5). Mean PSA nadir was 0.4 for patients with no evidence of disease (NED) and occurred at 33 months, 3.2 for LF at 17 months, 7.7 for DF at 12 months, and 1.4 for chemF at 24 months. After reaching the nadir, PSA in patients with recurrence followed first-order kinetics, rising exponentially over time. The mean PSA doubling time was 12.6 months for LF, 5.2 months for DF, and 21.8 months for chemF (P = 0.004). At last follow-up, the median PSA for patients without evidence of disease is 0.5 ng/mL. Four such patients had PSA values that rose to between 1 and 2 ng/mL for 5 to 38 months, but these eventually fell again to less than 1 ng/mL. Three patients had PSA values between 2 and 3 ng/mL, but 2 now have decreasing levels and the third has a rising level. All patients whose PSA levels rose to greater than 3 ng/mL exhibited a persistently rising pattern and ultimate tumor recurrence.


There is a range of PSA values following RT for PCa that is compatible with cure. A definition of biochemical disease-free status at any absolute threshold of PSA level less than 3 ng/mL will overdiagnose failure in a significant proportion of patients. Patients with a PSA level between 1.5 and 3 ng/mL should be observed until there is unequivocal evidence of disease recurrence. In the absence of known biopsy status, PSA doubling time can be a useful indicator of whether failure is local or distant.
View report here:

Take care
Allen Lai

Pattern of local failure following Radiation Therapy for Prostrate Cancer

A study report from Pub Med.Gov dated 14 May 2015



Little is known about patterns of local failure following radiation therapy (RT) for prostate cancer (PCa). We aimed to characterize post-radiation biopsy (PRB) findings, including the presence of treatment effect, and the zonal distribution of recurrent disease after RT in men experiencing biochemical recurrence (BCR).


We identified patients who received PRB in the setting of BCR following primary radiation for localized disease. Histologic PRB results were categorized by the absence of tumor, demonstration of radiation treatment effect, failure (recurrent cancer), or a combination of treatment effect and failure. We describe patterns of histologic failure and compared them to the diagnostic biopsy findings.


284 underwent mapped PRB for BCR. Mean age at initial diagnosis was 63 years, median PSA was 8.2 ng/ml; 33% of men were classified as low, 32% intermediate, and 35% high risk, based on clinical CAPRA categories. Median time to PRB was 61 months post-treatment and findings were negative in 4%, treatment effect in 31%, failure in 45%, and a combination in 20%. Failure rates were similar across sextants. Among 140 patients with mapped pre-and post-treatment biopsies, 4% demonstrated cancer in a new location previously identified as negative. Gleason upgrading occurred in 43%, with 85% upgraded ≥ 4+3.


Men with rising PSA after radiotherapy for PCa most often recur in dominant tumor sites. Whether failure is due to inadequate targeting, dosing or intrinsic radiation resistance remains unknown, and further study is warranted.

See study report here

take care

Allen Lai

Saturday, June 6, 2015

Rosetta Stone for Prostate Cancer found

Prostrate cancer cells

Researchers say that doctors could now start testing for the mutations and give patients with advanced prostate cancer existing drugs or drug combinations which are known to targeted the specific genomic aberrations

Hi all,

Read report published in Cell :

Almost 90 per cent of men with advanced prostate cancer carry genetic mutations in their tumours that could be targeted by either existing or new cancer drugs, a landmark new study reveals.
Scientists in the UK and the US have created a comprehensive map of the genetic mutations within lethal prostate cancers that have spread around the body, in a paper being hailed as the disease's 'Rosetta Stone'.

Researchers say that doctors could now start testing for these 'clinically actionable' mutations and give patients with advanced prostate cancer existing drugs or drug combinations targeted at these specific genomic aberrations in their cancers.

The study was led in the UK by scientists at The Institute of Cancer Research, London, in collaboration with researchers from eight academic clinical trials centres around the world.
Uniquely, doctors at The Royal Marsden NHS Foundation Trust and at hospitals in the US were able to collect large numbers of samples of metastatic cancers -- cancers that had spread from the original tumour to other parts of the body.

Normally these samples are extremely hard to access, and this is the first study in the world to carry out in-depth analysis of metastatic prostate cancers that are resistant to standard treatments.
The research is published in the journal Cell, and is funded by Stand up to Cancer and the Prostate Cancer Foundation.
Researchers analysed the genetic codes of metastatic tumours from the bone, soft tissues, lymph nodes and liver of 150 patients with advanced prostate cancer.
Nearly two thirds of the men in the study had mutations in a molecule that interacts with the male hormone androgen which is targeted by current standard treatments -- potentially opening up new avenues for hormone therapy.
Mutations in the BRCA1 and BRCA2 genes -- most famous for their roles in breast cancer -- were found in nearly 20 per cent of patients. Recent work at The Institute of Cancer Research (ICR) and The Royal Marsden has shown that these patients can be treated effectively by drugs called PARP inhibitors.
Researchers also discovered new mutations, never detected before in prostate cancer, but which do occur in other cancers. These include mutations in the PI3K and RAF gene families which can also be targeted by existing drugs, either currently in trials or approved for use in the clinic.
The researchers also took blood tests to analyse patients' own genomes, and found that 8 per cent were born with DNA errors that predisposed them to prostate cancer.
They said this could strengthen the case for genetic screening for people with a family history of the disease.
Previous genetic studies on prostate cancers had mostly analysed tissue from the primary tumours, which tend to carry fewer mutations than metastatic sites.
Studies of metastatic sites had been small and mostly used tissue taken during post mortems -- whereas in this study doctors took needle biopsies taken from patients during the course of their treatment.
Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Consultant at The Royal Marsden NHS Foundation Trust, said: "We have for the first time produced a comprehensive genetic map of the mutations in prostate cancers that have spread round the body. This map will guide our future treatment and trials for this group of different lethal diseases. We're describing this study as prostate cancer's Rosetta Stone -- because of the ability it gives us to decode the complexity of the disease, and to translate the results into personalised treatment plans for patients.
"Our study shines new light on the genetic complexity of prostate cancer as it develops and spreads -- revealing it to be not a single disease, but many diseases each driven by their own set of mutations. What's hugely encouraging is that many of the key mutations we have identified are ones targeted by existing cancer drugs -- meaning that we could be entering a new era of personalised cancer treatment."
Professor Paul Workman, Chief Executive and President of The Institute of Cancer Research, London, said: "Cancer becomes lethal at the stage when it spreads round the body and stops responding to treatment -- but until now it has been incredibly difficult to find out exactly what is going on genetically at that critical point.
"This major new study opens up the black box of metastatic cancer, and has found inside a wealth of genetic information that I believe will change the way we think about and treat advanced disease. The study found that almost 90 per cent of metastatic tumours had actionable mutations, which means that these findings could make a real difference to large numbers of patients."

Read BBC's article here:

Take care all

Allen Lai

The scientific link between happiness and exercise

Hi all,

View the scientific link between happiness and exercise.  Now that you know, be happy.

Visit the link below:

Take care

Allen Lai

Clinical trials are being conducted on diet for PCa

The diet plan

Hi all,

Clinical is currently offering qualified candidates to experiment and study on diet impact for PCA patients. This is a proposed two years programme.

For those who may not be able to participate you may view the above image for the proposed diet plan. Try it yourself as you have nothing to loose.

See the link to the trial requirements below:

Take care

Allen Lai

Thursday, June 4, 2015

Stable PSA

Hi all,

Today 2 June 2015, I am really very elated and happy to see my PSA level dropped to 0.17 from 0.19 from three months ago. It has been on a slow incline since August 2014 as expected. But showing a drop is just fantastic. All my dedication and efforts to fight off my cancer cells are paying off. I attribute my biggest gain came from my daily exercises.

Take care all,

Allen Lai